362 related articles for article (PubMed ID: 23437388)
1. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
Zhang B; McDaniel SS; Rensing NR; Wong M
PLoS One; 2013; 8(2):e57445. PubMed ID: 23437388
[TBL] [Abstract][Full Text] [Related]
2. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
[TBL] [Abstract][Full Text] [Related]
3. Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model.
Lozovaya N; Gataullina S; Tsintsadze T; Tsintsadze V; Pallesi-Pocachard E; Minlebaev M; Goriounova NA; Buhler E; Watrin F; Shityakov S; Becker AJ; Bordey A; Milh M; Scavarda D; Bulteau C; Dorfmuller G; Delalande O; Represa A; Cardoso C; Dulac O; Ben-Ari Y; Burnashev N
Nat Commun; 2014 Aug; 5():4563. PubMed ID: 25081057
[TBL] [Abstract][Full Text] [Related]
4. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
Rensing N; Han L; Wong M
Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
[TBL] [Abstract][Full Text] [Related]
5. Effects of antiepileptic drugs in a new TSC/mTOR-dependent epilepsy mouse model.
Koene LMC; van Grondelle SE; Proietti Onori M; Wallaard I; Kooijman NHRM; van Oort A; Schreiber J; Elgersma Y
Ann Clin Transl Neurol; 2019 Jul; 6(7):1273-1291. PubMed ID: 31353861
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
7. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
[TBL] [Abstract][Full Text] [Related]
8. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
Wong M
Epilepsia; 2010 Jan; 51(1):27-36. PubMed ID: 19817806
[TBL] [Abstract][Full Text] [Related]
9. Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy.
Ryther RC; Wong M
Curr Neurol Neurosci Rep; 2012 Aug; 12(4):410-8. PubMed ID: 22544534
[TBL] [Abstract][Full Text] [Related]
10. Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism.
Davis PE; Peters JM; Krueger DA; Sahin M
Neurotherapeutics; 2015 Jul; 12(3):572-83. PubMed ID: 25986747
[TBL] [Abstract][Full Text] [Related]
11. Cerebral vascular and blood brain-barrier abnormalities in a mouse model of epilepsy and tuberous sclerosis complex.
Guo D; Zhang B; Han L; Rensing NR; Wong M
Epilepsia; 2024 Feb; 65(2):483-496. PubMed ID: 38049961
[TBL] [Abstract][Full Text] [Related]
12. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
Nguyen LH; Mahadeo T; Bordey A
J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531
[TBL] [Abstract][Full Text] [Related]
13. Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis.
McMahon J; Huang X; Yang J; Komatsu M; Yue Z; Qian J; Zhu X; Huang Y
J Neurosci; 2012 Nov; 32(45):15704-14. PubMed ID: 23136410
[TBL] [Abstract][Full Text] [Related]
14. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex.
Liang N; Zhang C; Dill P; Panasyuk G; Pion D; Koka V; Gallazzini M; Olson EN; Lam H; Henske EP; Dong Z; Apte U; Pallet N; Johnson RL; Terzi F; Kwiatkowski DJ; Scoazec JY; Martignoni G; Pende M
J Exp Med; 2014 Oct; 211(11):2249-63. PubMed ID: 25288394
[TBL] [Abstract][Full Text] [Related]
15. Postnatal reduction of tuberous sclerosis complex 1 expression in astrocytes and neurons causes seizures in an age-dependent manner.
Zou J; Zhang B; Gutmann DH; Wong M
Epilepsia; 2017 Dec; 58(12):2053-2063. PubMed ID: 29023667
[TBL] [Abstract][Full Text] [Related]
16. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex.
Zhang B; Zou J; Rensing NR; Yang M; Wong M
Neurobiol Dis; 2015 Aug; 80():70-9. PubMed ID: 26003087
[TBL] [Abstract][Full Text] [Related]
18. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.
Di Nardo A; Kramvis I; Cho N; Sadowski A; Meikle L; Kwiatkowski DJ; Sahin M
J Neurosci; 2009 May; 29(18):5926-37. PubMed ID: 19420259
[TBL] [Abstract][Full Text] [Related]
19. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.
Schubert-Bast S; Rosenow F; Klein KM; Reif PS; Kieslich M; Strzelczyk A
Epilepsy Behav; 2019 Feb; 91():94-98. PubMed ID: 29941212
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.
Zeng LH; Xu L; Gutmann DH; Wong M
Ann Neurol; 2008 Apr; 63(4):444-53. PubMed ID: 18389497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
